PIMCO Closed-End Funds Declare Monthly Common Share

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PIMCO Closed-End Funds Declare Monthly Common Share Distributions

NEW YORK, NY--(Marketwired - Nov 1, 2016) -  The Boards of Trustees/Directors of the PIMCO closed-end funds (each, a "Fund" and, collectively, the "Funds") have declared a monthly distribution for each Fund's common shares as summarized below. The distributions are payable on December 1, 2016 to shareholders of record on November 14, 2016, with an ex-dividend date of November 9, 2016.

       
Fund NYSE Symbol   Monthly Distribution Per Share
  PIMCO Corporate & Income Strategy Fund (NYSE: PCN)   $ 0.112500
  PIMCO Corporate & Income Opportunity Fund (NYSE: PTY)   $ 0.130000
  PIMCO Global StocksPLUS® & Income Fund (NYSE: PGP)   $ 0.146680
  PIMCO High Income Fund (NYSE: PHK)   $ 0.103460
  PIMCO Income Opportunity Fund (NYSE: PKO)   $ 0.190000
  PIMCO Strategic Income Fund, Inc. (NYSE: RCS)   $ 0.080000
  PCM Fund, Inc. (NYSE: PCM)   $ 0.080000
  PIMCO Income Strategy Fund (NYSE: PFL)   $ 0.090000
  PIMCO Income Strategy Fund II (NYSE: PFN)   $ 0.080000
  PIMCO Dynamic Income Fund (NYSE: PDI)   $ 0.220500
  PIMCO Dynamic Credit and Mortgage Income Fund (NYSE: PCI)   $ 0.164063
  PIMCO Municipal Income Fund (NYSE: PMF)   $ 0.081250
  PIMCO California Municipal Income Fund (NYSE: PCQ)   $ 0.077000
  PIMCO New York Municipal Income Fund (NYSE: PNF)   $ 0.057000
  PIMCO Municipal Income Fund II (NYSE: PML)   $ 0.065000
  PIMCO California Municipal Income Fund II (NYSE: PCK)   $ 0.047300
  PIMCO New York Municipal Income Fund II (NYSE: PNI)   $ 0.066250
  PIMCO Municipal Income Fund III (NYSE: PMX)   $ 0.062300
  PIMCO California Municipal Income Fund III (NYSE: PZC)   $ 0.060000
  PIMCO New York Municipal Income Fund III (NYSE: PYN)   $ 0.052500

Distributions from PMF, PML, PMX, PCQ, PCK, PZC, PNF, PNI and PYN are generally exempt from regular Federal income taxes. In addition, distributions from PCQ, PCK and PZC are also generally exempt from California state income taxes, and distributions from PNF, PNI and PYN are generally exempt from New York State and city income taxes. There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.

Distributions may include ordinary income, net capital gains and/or returns of capital. Generally, a return of capital occurs when the amount distributed by a Fund includes a portion of (or is comprised entirely of) your investment in the Fund in addition to (or rather than) your pro-rata portion of the Fund's net income or capital gains. A Fund's distributions in any period may be more or less than the net return earned by the Fund on its investments, and therefore should not be used as a measure of performance or confused with "yield" or "income." A return of capital is not taxable; rather it reduces a shareholder's tax basis in his or her shares of the Fund. If a Fund estimates that a portion of its distribution may be comprised of amounts from sources other than net investment income, such Fund will notify shareholders of the estimated composition of such distribution through a separate written notice. Such notices are provided for informational purposes only, and should not be used for tax reporting purposes. Final tax characteristics of all Fund distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

It is important to note that differences exist between a Fund's daily internal accounting records, a Fund's financial statements prepared in accordance with U.S. GAAP, and recordkeeping practices under income tax regulations. It is possible that a Fund may not issue a Section 19 Notice in situations where the Fund's financial statements prepared later and in accordance with U.S. GAAP or the final tax character of those distributions might later report that the sources of those distributions included capital gains and/or a return of capital. Please see the Funds' most recent shareholder reports for more details.

A Fund's distribution rate may be affected by numerous factors, including changes in realized and projected market returns, Fund performance, and other factors. There can be no assurance that a change in market conditions or other factors will not result in a change in a Fund distribution rate at a future time.

Certain Funds may engage in investment strategies, including the use of derivatives, to, among other things, generate current, distributable income, even if such strategies could potentially result in declines in the Fund's net asset value. A Fund's income and gain-generating strategies, including certain derivatives strategies, may generate current income and gains taxable as ordinary income sufficient to support monthly distributions even in situations when the Fund has experienced a decline in net assets due to, for example, adverse changes in the broad U.S. or non-U.S. equity markets or the Fund's debt investments, or arising from its use of derivatives. A Fund may enter into opposite sides of interest rate swap and other derivatives for the principal purpose of generating distributable gains on the one side (characterized as ordinary income for tax purposes) that are not part of the Fund's duration or yield curve management strategies ("paired swap transactions"), with a substantial possibility that the Fund will later realize a corresponding capital loss and potential decline in net asset value with respect to the opposite side transaction (to the extent it does not have corresponding offsetting capital gains). Consequently, common shareholders may receive distributions and owe tax at a time when their investment in the Fund has declined in value, which tax may be at ordinary income rates, and which may be economically similar to a taxable return of capital. The tax treatment of certain derivatives may be open to different interpretations. Any recharacterization of payments made or received by a Fund pursuant to derivatives potentially could affect the amount, timing or character of Fund distributions. In addition, the tax treatment of such investment strategies may be changed by regulation or otherwise.

As with any stock, the price of a Fund's common shares will fluctuate with market conditions and other factors. Shares of closed-end management investment companies frequently trade at a price that is less than (a "discount") or more than (a "premium") from their net asset value. If a Fund's shares trade at a premium to net asset value, there is no assurance that any such premium will be sustained for any period of time and will not decrease, or that the shares will not trade at a discount to net asset value thereafter.

The Funds' daily New York Stock Exchange closing market prices, net asset values per share, as well as other information, including updated portfolio statistics and performance are available at pimco.com/closedendfunds or by calling the Funds' shareholder servicing agent at (844) 33-PIMCO. Updated portfolio holdings information about a Fund will be available approximately 15 calendar days after such Fund's most recent fiscal quarter end, and will remain accessible until such Fund files a Form N-Q or a shareholder report for the period which includes the date of the information.

About PIMCO

PIMCO is a leading global investment management firm with offices in 12 countries throughout North America, Europe and Asia. Founded in 1971, PIMCO offers a wide range of innovative solutions to help millions of investors worldwide meet their needs. Our goal is to provide attractive returns while maintaining a strong culture of risk management and long-term discipline. PIMCO is the investment manager of the Funds and is owned by Allianz S.E., a leading global diversified financial services provider.

Except for the historical information and discussions contained herein, statements contained in this news release constitute forward-looking statements. These statements may involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, including the performance of financial markets, the investment performance of PIMCO's sponsored investment products and separately managed accounts, general economic conditions, future acquisitions, competitive conditions and government regulations, including changes in tax laws. Readers should carefully consider such factors. Further, such forward-looking statements speak only on the date at which such statements are made. PIMCO undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statement.

This material has been distributed for informational purposes only and should not be considered as investment advice or a recommendation of any particular security, strategy or investment product. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission. PIMCO is a trademark of Allianz Asset Management of America L.P. in the United States and throughout the world. ©2016, PIMCO

For information on PIMCO Closed-End Funds: Financial Advisors: (800) 628-1237 Shareholders: (844) 337-4626 or (844) 33-PIMCO PIMCO Media Relations: (212) 739-4212

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 8

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 8

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 12

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 9

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 7

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 6

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 12

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 12

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing $1000 in Lockheed Martin: A Decade of Growth

Updated Category News Views 91

Unlocking the Power of $1000: The Journey of Lockheed Martin Lockheed Martin has excelled in the stock market, delivering impressive returns for investors who bought shares a decade ago. With a current market capitalization of $138.10 billion, this defense powerhouse has consistently outperformed the market, achieving an annualized growth rate that surpasses expectations....

Continue Reading
Fortis Financial Performance Update: Q4 Earnings Insights

Updated Category News Views 169

Fortis Financial Performance Overview Fortis (NYSE: FTS) has recently shared its Q4 earnings results, revealing strong performance that is worth a closer look. The company's earnings announcement not only highlights its financial health but also offers insights for investors and stakeholders alike. Earnings Highlights In its latest announcement, Fortis exceeded earnings...

Continue Reading
Flowers Foods Increases Quarterly Dividend to $0.24 Per Share

Updated Category News Views 100

Flowers Foods Declares Increased Quarterly Dividend Flowers Foods, Inc. (NYSE: FLO) has recently taken significant steps in its financial directives by announcing a quarterly dividend of $0.24 per share. This marks a commendable increase of 4.3% compared to the same quarter last year. Impressively, this is the 90th consecutive quarterly dividend paid by the company....

Continue Reading
Freeport McMoRan Adjusts Copper Sales Amid Production Setbacks

Updated Category News Views 65

Freeport McMoRan to Delay Indonesian Copper Sales Freeport McMoRan, a significant player in the copper mining industry, has announced a postponement of its refined copper sales from Indonesia to the second quarter of 2025. This decision follows a fire incident at its new smelter, causing an unexpected delay in production. Production Challenges at Manyar Smelter The Manyar...

Continue Reading
Snowflake and Palantir: Revolutionizing AI in Data Management

Updated Category News Views 240

Understanding the Important Deal Between Snowflake and Palantir Snowflake Inc. (NYSE: SNOW) has recently entered a significant partnership with Palantir Technologies Inc. (NYSE: PLTR), marking an important milestone in its ambitious journey towards enhancing artificial intelligence (AI) capabilities for businesses. This collaboration aims to foster enterprise AI...

Continue Reading